FOXO Technologies Reports Spinoff
FOXO Technologies Inc. (NYSE:FOXO) announced its Board of Directors has approved pursuing the spinoff of its FOXO Labs, Inc. subsidiary that is focused on the development of its epigenetics business
The West Palm Beach, Fla.-based company claims its Epigenetics subsidiary has been serving as a pioneer in the development and integration of epigenetic biomarkers into state-of-the-art underwriting protocols and consumer engagement tools. The company also owns the patent on the activity.
Epigenetic technology has been proven to provide health, lifestyle, and longevity insights that have never before been accessible to humans—from just a single saliva sample.
“Using saliva-based epigenetic biomarkers,” read this morning’s news release, “we’re eliminating the need for invasive blood and urine collection, allowing us to provide scientists with advanced epigenetic testing services and bioinformatics tools that support ground-breaking research.
Said CEO Mark White, “We are creating the ultimate health, fitness, and longevity coach leveraging our cutting-edge patented epigenetic analysis and a new proprietary AI model to deliver a deeply personalized coaching experience.
“Our AI coach first utilizes existing wellness data from wearable’s to offer hyper personalized foundational lifestyle guidance. Then, through unlocking deeper epigenetic analyses, we take a web of complex biological data and simplify it into an easily actionable plan to completely transform people’s journeys in health and wellness.”
FOXO shares ended Thursday trading at 12 cents.
